Toward the next waves of cancer immunotherapy: 11th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 14-16, 2013

摘要

With a record number of 760 international participants, 78 speakers and 264 abstracts, the 1 lth Annual Meeting of the Association for Cancer Immunotherapy (CIMT) launched into its second decade. Recent breakthroughs in the clinic were reached for immune-modulatory antibodies (e.g., ipilimumab), dendritic cell (DC)-based vaccines (e.g., Provenge) and adoptive transfer of immune-receptor-engineered lymphocytes [e.g., CD 19 chimeric antigen receptors (CARs)].